US 12,474,327 B2
Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1
Lynn Durham, Geneva (CH); and Jean-Marc Hyvelin, Geneva (CH)
Assigned to STALICLA SA, Geneva (CH)
Appl. No. 17/291,365
Filed by STALICLA SA, Geneva (CH)
PCT Filed Nov. 6, 2019, PCT No. PCT/EP2019/080450
§ 371(c)(1), (2) Date May 5, 2021,
PCT Pub. No. WO2020/094748, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/756,563, filed on Nov. 6, 2018.
Claims priority of application No. 18204769 (EP), filed on Nov. 6, 2018.
Prior Publication US 2022/0003753 A1, Jan. 6, 2022
Int. Cl. G01N 33/52 (2006.01); G01N 33/50 (2006.01)
CPC G01N 33/5091 (2013.01) [G01N 2800/28 (2013.01)] 7 Claims
 
1. A method comprising:
a) providing a cell line from a typically developing control;
b) providing a patient-specific cell line from a patient;
c) contacting both the typically developing control cell line and the patient-specific cell line with a first carbon source of energy wherein the carbon source of energy is one or more selected from the group consisting of maltose, turanose, D-treahalose, sucrose, maltotriose, inosine;
wherein the energy production capacity of said patient-specific cell line is different from the cell line from a typically developing control in that it has a higher energy production capacity in the presence of the first carbon energy source than the typically developing control,
wherein the cell lines are lymphoblastoid cell lines and wherein the patient has been previously diagnosed with idiopathic autism spectrum disorder (ASD).